Angelalign's overseas cases increased by 82%, as the domestic orthodontic giant is "racing" abroad

How does Angelalign achieve rapid overseas market growth through word-of-mouth?

【Written by Wang Li, Edited by Zhou Yuanfang】

On March 27, Angelalign Technology Co., Ltd. (06699.HK) released its annual performance announcement for the fiscal year 2025. The performance report shows that the company achieved an annual revenue of $370.3 million, a year-on-year increase of 37.8%; a net profit of $26.3 million, a year-on-year increase of 163.0%; an adjusted net profit of $43.77 million, a year-on-year increase of 62.99%; and a total case count of 532,400 for the year, a year-on-year increase of 48.1%.

This leading invisible orthodontics company based in Wuxi once fell into a continuous profit decline due to domestic procurement pressures from 2022 to 2023, with its market value dropping by over 80% from a peak of over HKD 70 billion. However, the performance data for 2025 indicates that its globalization strategy is realizing incremental logic—not relying on price wars, but instead building a word-of-mouth driven growth flywheel by penetrating the global top orthodontic community.

It is noteworthy that this performance is not derived from simple scale expansion. In 2025, the number of cases in overseas markets (excluding mainland China) increased by 82.1% year-on-year, while revenue increased by 102.5%, far exceeding the 26.3% case growth and 10.1% revenue growth in the mainland Chinese market; the revenue from overseas markets now accounts for nearly 44% of the group’s total revenue, up from 30% in 2024. Meanwhile, the adjusted segment profit from the mainland Chinese market also rose from $36.64 million to $51.31 million, indicating that the domestic foundation is becoming more robust amid a reshuffling of the competitive landscape.

However, beyond the impressive data, potential risks do exist. The loss in the overseas market segment has narrowed significantly from $29.65 million in 2024 to $10.54 million, yet it remains in the loss zone; financial asset impairment losses have surged year-on-year to $8.2 million, primarily due to the deterioration of financial conditions of several counterparties leading to receivables impairment; multi-country patent litigation initiated by Align Technology is still ongoing, and the legal risk exposure is difficult to quantify. Whether this company can maintain profit quality while accelerating expansion is a core question for the market to observe in the next stage.

Overseas Business: Strategic Transition from Scale Output to Word-of-Mouth Driven Growth

To understand the quality of Angelalign’s growth in overseas markets in 2025, it is essential to examine it within the competitive characteristics of the invisible orthodontics industry. Unlike the logic of fast-moving consumer goods exports, orthodontic treatment cycles typically last one to two years, with the use of dozens to hundreds of aligners, where differences in product precision and plan design quality can be amplified over time. This means that entering a national market does not equate to winning that market—the real barrier lies in whether one can gain clinical recognition from local top orthodontic experts and leverage professional community word-of-mouth to create a chain reaction.

From this perspective, Angelalign’s global expansion path in 2025 shows inherent strategic consistency. The company chooses to prioritize deepening its presence in first-tier cities such as New York, London, Paris, Tokyo, Sydney, and Boston, rather than opening channels for volume. The core logic is that first-tier cities concentrate the most demanding orthodontic specialists regarding clinical outcomes; once credibility is established within this group, its influence will radiate to a broader community of doctors. According to the announcement, hundreds of international orthodontic experts have cumulatively used Angelalign products in over 100 cases, with some experts exceeding 1,000 cases, focusing on complex cases—this endorsement for high-difficulty cases is far more persuasive than the mere accumulation of conventional case numbers.

From a financial structure perspective, the revenue breakdown for the overseas market in 2025 is also noteworthy. Revenue from “sales of invisible aligners” surged 108.6% from $74.01 million in 2024 to $154.4 million, with a growth rate nearly ten times that of the mainland China’s “invisible aligner solutions” revenue growth (10.4%) during the same period. This divergence is attributed to a downward shift in average prices due to changes in product mix in the Chinese market, coexisting with rapid case volume growth in overseas markets. The differentiated rhythm of these two growth engines objectively reflects the different developmental stages of the two markets.

However, the rapid expansion in overseas markets has also brought cost pressures that warrant continuous monitoring. In 2025, sales and marketing expenses reached $121.5 million, a year-on-year increase of 15.7%. However, thanks to the operational leverage effect driven by scale expansion, the sales expense ratio has decreased from 39.1% in 2024 to 32.8%, which is a commendable structural improvement signal. R&D expenses increased by 29.7% year-on-year to $27.64 million, reflecting the company’s ongoing investment in clinical innovation—establishing industry-university-research collaborations at over 40 universities in Europe, America, Asia-Pacific, and China, and advancing cutting-edge technology layouts such as direct 3D printing to position itself for the next generation of product matrices.

At the same time, the progress in diversifying the supply chain layout provides robust support for sustained global business expansion. The Brazilian manufacturing center has officially begun production of Angelalign brand aligners, providing nearby supply for the South American market; the Southeast Asia medical design center and production base have been fully established; and the U.S. production base is under construction, exploring small-scale automated production paths. This “multi-center” layout not only reduces geopolitical risks but also shortens delivery times and improves local service responsiveness, making it one of the foundational guarantees for the continuous improvement of overseas market NPS (Net Promoter Score).

However, the ongoing expansion of global business is not without uncertainties. Starting August 2025, Align Technology initiated several patent infringement lawsuits against Angelalign in the U.S. (including the Eastern District of Texas and ITC), Europe (Unified Patent Court), and China (Intermediate People’s Court, National Intellectual Property Administration). As of December 31, 2025, the related cases are still in the trial stage.

Additionally, in February this year, the Unified Patent Court in Düsseldorf, Germany issued a temporary injunction regarding specific software functions, which the company subsequently addressed through technical adjustments, and the related impact has been partially absorbed within the year. However, the overall legal process remains uncertain, and potential injunctions, settlement costs, or damages could materially affect operational performance and cash flow. This unresolved legal variable will continue to influence market expectations regarding the company’s global expansion trajectory.

Mainland China Market: Structural Benefits and Profit Release After Procurement Restructuring

If the overseas market represents a new chapter in Angelalign’s growth story, the mainland China market serves as the core pillar supporting its current profit performance. In 2025, the mainland China market achieved 276,200 cases (a year-on-year increase of 26.3%), revenue of $207.3 million (a year-on-year increase of 10.1%), and adjusted segment profit of $51.31 million (up 40% from $36.64 million in 2024), accounting for approximately 56% of the group’s total revenue. In terms of segment profit contribution, the adjusted profit from the mainland China market essentially covers the overall profit of the group, while the overseas market is still in a state of investment-related losses.

The revenue growth rate (10.1%) is significantly lower than the case growth rate (26.3%), reflecting two concurrent structural changes in the domestic market: first, under the backdrop of procurement, the prices of invisible aligners have continued to decline, with the product mix shifting towards lower-tier markets and early treatment, leading to a contraction in average selling prices; second, the rapid growth of business in third- and fourth-tier cities compensates for the price compression from a quantitative perspective. In 2025, as some small and medium brands exited the market due to an inability to maintain continuous supply, Angelalign further expanded its market share in lower-tier markets.

The announcement revealed a detail with significant industry implications: some discontinued invisible aligner brands actively suggested partnering doctors, with patient consent, to transfer ongoing cases to leading brands and assist in completing subsequent treatment handovers. This orderly exit model objectively reduces the friction costs of market clearing and makes the sources of incremental growth for Angelalign in lower-tier markets more diverse—comprising both newly developed third- and fourth-tier doctors and legacy cases inherited from exited brands. This rapid increase in market concentration has already been fully reflected in case numbers.

At the same time, the increasing proportion of early treatment and pediatric orthodontics presents another long-term growth clue worth tracking in the mainland China market. In 2025, Angelalign launched a pediatric anti-caries aligner, integrating tooth correction with caries prevention functions, opening up differentiated pricing space; “Angelalign KiD” has ranked first in search indices on mainstream social platforms, further deepening brand penetration among Generation Z parents. Compared to the relatively transparent pricing competition in the adult orthodontics market, the pediatric early treatment sector has higher barriers in terms of technical thresholds, doctor training requirements, and patient demand identification, making it an important direction for leading brands to build differentiated moats.

From the perspective of profit quality, the improvement in the mainland China’s market profitability has a sustainable foundation. The administrative expense ratio decreased from 17.2% to 14.1%, and the sales expense ratio decreased from 39.1% to 32.8%. The simultaneous decline of these two ratios indicates that the group is realizing genuine operational leverage release rather than sacrificing input for short-term profits. After the global business scale expands, R&D and back-office costs can be effectively diluted, serving as a fundamental driver of this improvement.

It is noteworthy that in 2025, financial asset impairment losses reached $8.2 million, a sharp increase from $150,000 in 2024, primarily due to the deterioration of financial conditions of several counterparties leading to impairments of trade receivables and other receivables. This unusual increase signals that, during the process of scale expansion, especially in the context of rapid penetration into lower-tier markets, credit risk management for receivables needs to be strengthened in sync with business growth.

At the capital structure level, the company’s debt-to-asset ratio remains in a healthy range, with bank borrowings of only $2.5 million and a debt-to-asset ratio of 0.5%; cash and cash equivalents totaled $444.9 million, with a current ratio of 3.0 times, providing sufficient financial stability for global operations. The board announced a final dividend of HKD 0.48 per share and a special dividend of HKD 4.99 per share, with the high proportion of the special dividend reflecting the willingness to return to shareholders while also testing the company’s accuracy in forecasting its future cash flow needs.

In summary, the core narrative of Angelalign’s 2025 performance is that the reshuffling of the domestic competitive landscape provides profit support, with its globalization strategy moving past the early investment phase into a self-reinforcing stage driven by word-of-mouth. This represents a turning point in a business model that merits reevaluation by the market. However, uncertainties regarding the profit cycle in the overseas market, unresolved legal litigation, and ongoing pressure from changes in the domestic product mix on revenue growth collectively constitute the hurdles that must be overcome before this story can reach a more optimistic conclusion.